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Receptor status was considered by reviewing each individual receptor: ER (Estrogen Receptor), PR (Progesterone Receptor), HER2 (HER2/neu Receptor); but newer approaches look at these together, along with the tumor grade, to categorize BC into several molecular subclasses (Prat and Perou, 2011) that have different prognoses (Genestie et al., 1998) and may have different responses to specific therapies. Researchers are looking for how molecular subtypes of BC may be useful in planning treatment and developing new therapies. Most studies divide breast cancer into four major molecular subtypes: luminal A (ER+ and/or PR+, HER2-,), luminal B (ER+ and/or PR+, HER2+), HER2-like (ER-, PR-, HER2+) and basal like/triple negative (ER-, PR-, HER2-). The prevalences of molecular subtypes were aproximately as follows: luminal A 40%, luminal B 20%, basal like/ triple negative 15-20% , HER2-like 10-15% (Potemski et al., 2005; Fan et al., 2006; Hu et al., 2006; Schnitt, 2010; Voduc et al., 2010; Carey, 2013) . Luminal A and B groups are the most common molecular sub-groups.
Luminal A has the best prognosis, whereas the basallike/triple negative (BL/TN) has the worst prognosis. Although tumors with HER2-like have bad prognosis, HER2 targeted therapies have changed the outcome (Carey et al., 2006; Fan et al., 2006; Hu et al., 2006; Loi et al., 2007; Voduc et al., 2010; Carey, 2013) .
In present study, we aimed to investigate the relationship between molecular subtypes and NACT in patients with BC. VI and PNI (p=0.798, p=0.473, p=0.507, p=0.064, p=0.066, p=0.612, p=0.100, p=0.223, p=0.897, p=0 .853 respectively). There was a significant difference between the molecular subtypes for grade (p<0.001). BL/TN group mostly had N2 disease (58.8%), while other groups had generally N1 disease. The ratio of T4 stage was higher in luminal B and HER2-like tumors than luminal A and BL/TN subtypes (20%, 30.3%, 30.8%, 5.9% respectively). Concurrent or sequential Antracyclin and taxane based chemotherapy were the most used NACT regimens in all subtypes. Antracycline alone was the second most preferred regimen. 60.6% of the patients with luminal B and 26.9% of HER2-like BC had not taken trastuzumab as NACT. Molecular shifting rate was higher in luminal A type than the others after NACT; 28.6% of Luminal A, 14.3% of Luminal B, none of HER2-like, 20% of BL/TN have shifted to other subtypes (p<0.001) ( Table 2 ). After NACT, tumoral (T) and nodal (N) downstaging ratios were shown in Figure 1 and 2.
Materials and Methods
Pathological CR in breast after NACT were as follows: 3.8% for luminal A, 35.5% for luminal B, 47.8% for HER2-like type and 61.5% for BL/TN type (p=0.001). pCR rates in axillary after NACT were as follows: 15.8% for luminal A, 38.5% for luminal B, 57.9% for HER2-like type and 693.6% for BL/TN type (p=0.022). pCR in breast and axillary was significantly higher among patients with HER2-like type than the others (p=0.018). pCR rates were shown in Table 3 .
Discussion
More than 70% of patients achieve objective response (including pathological complete remission in 10-25% of cases) and many patients experience down-staging via NACT (Ferley et al., 2010) .
It had been shown that luminal A group had the best disease free survival (DFS) rate while the worst DFS rate was among the HER2-like group (Najafi, 2013) . It had been reported that improved survival outcomes were observed in patients with pCR compared with those with residual tumor. The association between pCR and long-term survival was weakest for luminal groups and low grade tumors. On the other hand it was shown that association between pCR and long-term outcome was strongest in patients with aggressive breast cancer subtypes. In some studies, it was reported that pCR was not a prognostic factor in luminal A or luminal B and HER2-positive breast cancer (Wolmark et al., 2001; von Minckwitz et al., 2011; von Minckwitz et al., 2012; Cortazar et al., 2014) . Some groups have reported that basal-like and HER2-like tumors showed the higher pathological complete response rate than luminal groups (Parker et al., 2009; Lv et al., 2011; Khokher et al., 2013) . In the present study; relatively higher pCR rates were achieved locally (axillary or breast) among luminal B, HER2-like and TN/ BL subtypes than that in previous studies. But there were relatively lower response rates in luminal A subtype than previous studies. There was no pCR in luminal A subtype for both breast and axillary region.
We found pCR rate was significantly (p=0.018) higher among patients with HER2-like (36.4%) and BL/TN (27.3%) than luminal tumors (0.0% and 21.4% for luminal A and B respectively) in both breast and axillary region. Similarly, it was reported that the pCR to NACT was significantly better among basal-like (27%) and HER2-like tumors versus luminal tumors (7%) (Carey et al., 2007) .
In some studies with all stages, high grade was associated with non-luminal subtypes (Kadivar et al., 2012; Engstrøm et al., 2013) . This observation is not consistent with present study. In this study luminal B group had the higher grade than the other subtypes. In the other studies the luminal type BC were well differentiated, low TNM profile tumors with a low Ki-67 proliferation index (Irigoyen et al., 2011; Widodo et al., 2014) . On the contrary, the basal type and HER2 carcinomas presented higher TNM profile, poorly differentiated tumors with high Ki-67 proliferation indexes (Irigoyen et al., 2011; Chuthapisith et al., 2012) . Similarly, in this study earlier stages (stage I-II), lower Ki-67 indexes, lesser axillary nodal involvement associated with luminal A subtype whereas non-luminal subtypes showed more aggressive tumor characteristics especially high grade, Ki-67, LVI, PNI, clinical stage (stage III) tumors.
Breast tumor response to NACT varied among the different molecular subtypes. Ruano, et al reported this response was lowest in luminal A and highest in nonluminal HER2+ group. Also HER2+ and triple-negative were were shown to be the groups with the best axillary histological response (Ruano et al., 2014) . Present study was in the same line with literature as follows: primary tumor response rates were 3.8% in luminal A, 47.8% in HER2-like type and 61.5% in BL/TN type. Axillary response rates were 15.8% in luminal A, 57.9% in HER2-like, 63.6% in BL/TN type. This study revealed that breast cancer subtypes are in relation with the response to NACT (table 5). In the literature it was reported that after the NACT more than 30% reduction in primary tumor size in 74.2% of patients were observed (Egwuonwu et al., 2013) . In present study the most tumoral (T) downstaging was in BL/TN subtype and nodal downstaging was higher in HER2-like and BL/TN subtpypes than luminal subtypes (Figure 1-2) .
This study demonstrated that the pCR rate in breast and axillary were the significantly higher in patients with HER2-like type BC. It was known that patients with pCR had excellent prognosis. According to our study results, we speculate that NACT may be offered in early stage HER-2 like especially >2cm tumors as in Techno, NeoALLTo, NeoSphere and GeparQuinto studies Baselga et al., 2012; Gianni et al., 2012; Untch et al., 2012) . Molecular shifting after NACT was more frequently observed in Luminal A type tumors. Particularly in this group the treatment schedule should be rewieved again after NACT.
